Kopran Dividend

What does Kopran do? Kopran Ltd. generates revenue through the manufacturing and sale of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company produces penicillin-based finished oral dosage forms such as anti-infective, amoxycillin, ampicillin, cloxacillin, and amoxy clauv, as well as non-penicillin-based formulations including macrolides, anti-hypertensive, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, and gastroenterology products. Additionally, Kopran supplies APIs like anti-hypertensive, macrolides, neuromodulator, urological, anti-infective/anti-acne, sterile carbapenems, and sterile cephalosporins. These products are sold to healthcare providers, distributors, and pharmaceutical companies seeking reliable sources of finished dosage forms and APIs for their own manufacturing processes. The company's product portfolio targets multiple therapeutic segments including anti-infective, cardiovascular, and gastrointestinal treatments. Its formulations cater to both penicillin and non-penicillin-based medical needs, while APIs support a broad range of pharmaceutical applications. Kopran's manufacturing focus on finished dosage forms and APIs enables it to serve the pharmaceutical industry's demand for essential drug components without direct consumer sales. Kopran Ltd. primarily serves pharmaceutical manufacturers and healthcare distributors who require high-quality active ingredients and finished drug products. The firm's production of capsules, injectables, and tablets ensures its offerings meet diverse market needs. By specializing in both formulation and API manufacturing, Kopran positions itself as a key supplier within the pharmaceutical supply chain, providing critical components for various medical treatments. Kopran is one of the most popular companies on Eulerpool.